Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma.
17p13 deletion
Fluorescence in situ hybridization
Prognosis
Renal cell cancer
Tissue microarray
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
13 Jun 2020
13 Jun 2020
Historique:
received:
15
03
2020
accepted:
02
06
2020
entrez:
15
6
2020
pubmed:
15
6
2020
medline:
15
4
2021
Statut:
epublish
Résumé
Deletions of 17p13 recurrently occur in renal cell carcinoma (RCC) but their prognostic role seems to be uncertain. To determine prevalence, relationship with tumor phenotype, and patient prognosis, a tissue microarray containing samples from 1809 RCCs was evaluated using dual labeling fluorescence in situ hybridization (FISH) with 17p13 and chromosome 17 centromere probes. A 17p13 deletion was found in 72 of 1429 interpretable tumors. The frequency of 17p13 deletions varied greatly between RCC subtypes and was highest in chromophobe RCC (24/72; 33.3%). 17p13 deletions were also found in 35 (3.7%) of 946 clear cell RCC, 9 (4.3%) of 208 papillary RCC, 1 of 121 oncocytomas (0.8%), as well as in several rare cases of comprising 1 of 7 Xp11.2 translocation cancers, 1 of 3 collecting duct carcinomas, and 1 of 20 not otherwise specified (NOS) carcinomas. In clear cell carcinomas, 17p13 deletions revealed a strong and consistent association with higher Fuhrman, ISUP, and Thoenes grade (p < 0.0001 each), and linked to advanced tumor stage (p = 0.0168), large tumor diameter (p = 0.0004), distant metastases (p = 0.0077), cancer-specific survival (p = 0.0391), and recurrence-free survival (p = 0.0072). In multivariate analysis, 17p13 deletions showed in clear cell RCC a dependent prognostic role for established clinical-pathological parameters. 17p13 deletions have a dual role in RCC. They are associated with disease progression in clear cell RCC and possibly other subtypes and they are linked to the development of chromophobe RCC-a subtype with a particularly favorable prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Deletions of 17p13 recurrently occur in renal cell carcinoma (RCC) but their prognostic role seems to be uncertain.
METHODS
METHODS
To determine prevalence, relationship with tumor phenotype, and patient prognosis, a tissue microarray containing samples from 1809 RCCs was evaluated using dual labeling fluorescence in situ hybridization (FISH) with 17p13 and chromosome 17 centromere probes.
RESULTS
RESULTS
A 17p13 deletion was found in 72 of 1429 interpretable tumors. The frequency of 17p13 deletions varied greatly between RCC subtypes and was highest in chromophobe RCC (24/72; 33.3%). 17p13 deletions were also found in 35 (3.7%) of 946 clear cell RCC, 9 (4.3%) of 208 papillary RCC, 1 of 121 oncocytomas (0.8%), as well as in several rare cases of comprising 1 of 7 Xp11.2 translocation cancers, 1 of 3 collecting duct carcinomas, and 1 of 20 not otherwise specified (NOS) carcinomas. In clear cell carcinomas, 17p13 deletions revealed a strong and consistent association with higher Fuhrman, ISUP, and Thoenes grade (p < 0.0001 each), and linked to advanced tumor stage (p = 0.0168), large tumor diameter (p = 0.0004), distant metastases (p = 0.0077), cancer-specific survival (p = 0.0391), and recurrence-free survival (p = 0.0072). In multivariate analysis, 17p13 deletions showed in clear cell RCC a dependent prognostic role for established clinical-pathological parameters.
CONCLUSION
CONCLUSIONS
17p13 deletions have a dual role in RCC. They are associated with disease progression in clear cell RCC and possibly other subtypes and they are linked to the development of chromophobe RCC-a subtype with a particularly favorable prognosis.
Identifiants
pubmed: 32534597
doi: 10.1186/s12957-020-01902-y
pii: 10.1186/s12957-020-01902-y
pmc: PMC7293794
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
128Références
J Pathol. 1997 Feb;181(2):136-9
pubmed: 9120715
Cancer Res. 1993 Jul 1;53(13):3092-7
pubmed: 8319216
J Urol. 1993 Oct;150(4):1298-301
pubmed: 8103806
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2170-5
pubmed: 26864202
Cancer Res. 1991 Mar 1;51(5):1544-52
pubmed: 1671759
World J Urol. 2018 Sep;36(9):1341-1353
pubmed: 29610964
World J Urol. 2020 May 2;:
pubmed: 32361874
Pathol Int. 1997 Feb-Mar;47(2-3):79-83
pubmed: 9088024
Mod Pathol. 2011 Nov;24(11):1470-9
pubmed: 21725288
Histopathology. 2004 Jun;44(6):542-6
pubmed: 15186268
Cancer. 2013 Apr 15;119(8):1547-54
pubmed: 23335244
Oncotarget. 2017 Jan 3;8(1):379-392
pubmed: 27880722
BMC Cancer. 2009 May 18;9:152
pubmed: 19445733
Cancer Res. 2001 Jun 1;61(11):4514-9
pubmed: 11389083
Int J Cancer. 2009 Nov 15;125(10):2342-8
pubmed: 19521957
Oncol Rep. 1998 Jul-Aug;5(4):923-6
pubmed: 9625847
Nat Commun. 2019 Feb 7;10(1):632
pubmed: 30733432
Am J Clin Pathol. 2010 Jan;133(1):116-26
pubmed: 20023267
Am J Pathol. 2012 Aug;181(2):401-12
pubmed: 22705054
Urol Oncol. 2020 Jun;38(6):605.e1-605.e8
pubmed: 32241691
Adv Exp Med Biol. 2018;1044:135-148
pubmed: 29956295
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
J Clin Oncol. 2017 Feb 20;35(6):591-597
pubmed: 28199818
Oncotarget. 2016 Dec 6;7(49):81322-81331
pubmed: 27835607
Biomed Res Int. 2015;2015:476508
pubmed: 26448938
Cytogenet Cell Genet. 2001;93(3-4):221-7
pubmed: 11528115
BMJ. 2014 Nov 10;349:g4797
pubmed: 25385470
Hum Pathol. 2013 Aug;44(8):1524-33
pubmed: 23465274
Mol Urol. 2001 Spring;5(1):11-7
pubmed: 11689146
Am J Pathol. 1998 Nov;153(5):1467-73
pubmed: 9811338
Int J Cancer. 1995 Dec 20;64(6):399-406
pubmed: 8550242
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Cancer Res. 1991 Nov 1;51(21):5817-20
pubmed: 1682036
J Pathol. 1999 Feb;187(3):308-12
pubmed: 10398084
J Cancer Res Clin Oncol. 2019 Mar;145(3):625-636
pubmed: 30542790
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2854-8
pubmed: 7708737
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Urol Oncol. 2020 Feb;38(2):43.e13-43.e20
pubmed: 31757738
Br J Cancer. 1994 Feb;69(2):230-4
pubmed: 8297719
Cancer Res. 1993 Dec 1;53(23):5780-3
pubmed: 8242636
Int J Cancer. 2015 Nov 15;137(10):2354-63
pubmed: 26009879
Eur Urol. 2019 May;75(5):799-810
pubmed: 30803729
Hum Pathol. 2015 Jan;46(1):9-16
pubmed: 25439741
World J Urol. 2013 Aug;31(4):847-53
pubmed: 22009118
Clin Cancer Res. 2013 Sep 1;19(17):4673-84
pubmed: 23817689
Sci Rep. 2017 Nov 16;7(1):15698
pubmed: 29146923
Cancer Res. 1992 Apr 1;52(7):1881-5
pubmed: 1348014
Int J Cancer. 1996 Sep 27;68(1):47-50
pubmed: 8895539
J Pathol. 1992 Jul;167(3):273-7
pubmed: 1381433
J Clin Oncol. 2009 Feb 10;27(5):746-53
pubmed: 19124809
World J Urol. 1994;12(3):162-8
pubmed: 7951344
Genes Chromosomes Cancer. 2001 Jun;31(2):156-71
pubmed: 11319803
Am J Surg Pathol. 2002 Dec;26(12):1542-52
pubmed: 12459621
Am J Pathol. 1994 Aug;145(2):356-64
pubmed: 7519827
Cancer Res. 1991 Feb 1;51(3):820-3
pubmed: 1670999
Urol Oncol. 2014 Jul;32(5):601-6
pubmed: 24629495
Am J Pathol. 2013 Apr;182(4):1163-70
pubmed: 23416164